Orexigens naltrexone SR shows efficacy in Phase I

Data presented at the Obesity Society Annual Scientific Meeting show Orexigen Therapeutic’s sustained release formulation of naltrexone, Contrave, achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials.